Table 3.
Ongoing studies without results in patients with EGFR mutant lung cancers.
| Target | Agents | Clinical trials | Phase | Status |
|---|---|---|---|---|
| 1st/2nd gen EGFR TKI | Erlotinib/Gefitinib | Pulsatile Erlotinib or Gefitinib (NCT01965275) | 2 | Ongoing |
| Erlotinib | High/low dose Erlotinib (first line) (NCT01967095) | 1 | Ongoing | |
| Afatinib | Pulsatile Afatinib (NCT01647711) | 1 | Ongoing | |
| Afatinib + Nimotuzumab | (NCT01861223) | 1B | Ongoing | |
| Mutant-specificTKI | ASP8273 | (NCT02113813) | 1 | Ongoing |
| EGF816 | (NCT02108964) | 1 | Ongoing | |
| Chemotherapy | Bevacizumab | Erlotinib +/- Bev (first-line) (NCT01532089) | 2 | Ongoing |
| Platinum/Gem | Erlotinib +/- chemo (first-line) (NCT02001896) Erlotinib + chemo (NCT02098954) |
3 2 |
Not yet open Not yet open |
|
| Platinum/Pemetrexed | Chemo +/- Erlotinib (NCT01928160) | 2 | Not yet open | |
| Platinum doublet | Chemo +/- Erlotinib (NCT02064491) | 2 | Ongoing | |
| MET | Crizotinib | Crizotinib + Dacomitinib (NCT01121575) | 1 | Completed |
| Tivatinib (ARQ197) | Erlotinib +/- ARQ197 (NCT00777309) | 2 | Completed | |
| Cabozantinib (XL184) | XL184 +/- Erlotinib (NCT00596648) XL184 + Erlotinib (NCT01866410) |
1/2 2 |
Completed Ongoing | |
| INC280 | INC280 + Gefitinib (NCT01610336) INC280 + Erlotinib (NCT01911507) |
2 1 |
Ongoing Ongoing |
|
| Onartuzumab (METMab) | Erlotinib +/-METMab (first line) (NCT01887886) | 3 | Ongoing | |
| LY2875358 | LY2875358 +/- Erlotinib (NCT01900652) | 2 | Ongoing | |
| MSC2156119J | MSC2156119J + Gefitinib in p1 (NCT01982955) | 1B/2 | Ongoing | |
| HGF | Rilotumumab (AMG102) | Rilotumumab + Erlotinib (NCT01233687) | 1/2 | Ongoing |
| HER2 | Trastuzumab | Trastuzumab (NCT00004883) | 2 | Completed |
| IGF-1R | OSI-906 | Erlotinib +/- OSI-906 (first line) (NCT01221077) | 2 | On hold |
| AXL | Foretinib | Foretinib + Erlotinib (NCT02034097) | 2 | Not yet open |
| MEK | MEK162 | MEK162 + Erlotinib (NCT01859026) | 1 | Ongoing |
| AZD6244 | AZD +/- Erlotinib (NCT01229150) | 2 | Ongoing | |
| Selumetinib | Selumetinib + Gefitinib (NCT02025114) | 1B/2 | Not yet open | |
| AKT | MK-2206 | MK-2206 + Gefitinib (NCT01147211) | 1 | Completed |
| PI3K | BKM120 | BKM120 + Erlotinib (NCT01487265) | 2 | Ongoing |
| XL147 | XL147 + Erlotinib (NCT00692640) | 1 | Completed | |
| mTOR | XL765 (also PI3K-I) | XL765 + Erlotinib (NCT00777699) | 1 | Completed |
| Sirolimus | Sirolimus + Afatinib (NCT00993499) | 1 | Ongoing | |
| Everolimus | (NCT00124280) | 2 | Completed | |
| HSP90 | SNX-5422 | SNX-5422 + Erlotinib (NCT01851096) | 1 | Completed |
| DS-2248 | DS-2248 (NCT01288430) | 1 | Ongoing | |
| Immunotherapy | MPDL3280A (PD-L1) | MPDL3280A + Erlotinib (first-line) (NCT02013219) | 1B | Ongoing |
| MK-3475 (PD-1) | MK-3475 + Erlotinib, MK-3475 + Gefitinib (NCT02039674) | 1/2 | Ongoing | |
| Other | Metformin | Gefitinib +/- Metformin (first-line) (NCT01864681) | 2 | Ongoing |
| Hydroxychloroquine | Hydroxychloroquine + Gefitinib (NCT00809237) | 1/2 | Ongoing |
A=afatinib, E=erlotinib, G=gefitinib